Proellex®, is an orally active, small molecule, selective blocker of the progesterone receptor that we are developing for three indications: pre-surgical short course treatment of anemia associated with uterine fibroids (currently in Phase 3), chronic treatment of uterine fibroids (currently in Phase 3), and endometriosis (currently in Phase 2). In addition, we are also conducting two large open Label Safety Studies with Proellex.
We believe Proellex may have advantages in treating these indications as compared to surgery or the most effective drug therapies on the market which are gonadotropin releasing agonists, or GnRH agonists, which can not be used for longer than six months due to issues relating to permanent bone loss. In our clinical trials to date, women treated with Proellex maintain baseline estrogen levels, therefore, we believe Proellex treatment will not result in estrogen deprivation and loss of bone mineral density. We believe Proellex may provide an attractive alternative to surgery because of its potential to treat these conditions in a long-term or chronic fashion, resolving the symptoms that most commonly lead to surgical treatment.